148 related articles for article (PubMed ID: 29702731)
1. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
[TBL] [Abstract][Full Text] [Related]
2. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
[TBL] [Abstract][Full Text] [Related]
3. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
[TBL] [Abstract][Full Text] [Related]
9. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
[TBL] [Abstract][Full Text] [Related]
10. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
[TBL] [Abstract][Full Text] [Related]
11. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance.
Hu S; Wang T; You H; Chen S; Zhang T; Dong Y
J Clin Pharm Ther; 2022 Oct; 47(10):1548-1555. PubMed ID: 35633105
[TBL] [Abstract][Full Text] [Related]
12. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis.
Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
[TBL] [Abstract][Full Text] [Related]
15. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
[TBL] [Abstract][Full Text] [Related]
16. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
[TBL] [Abstract][Full Text] [Related]
17. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
[TBL] [Abstract][Full Text] [Related]
18. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
[TBL] [Abstract][Full Text] [Related]
19. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
Wang JT; Liao HI; Wu Lin FL; Chang SC
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
[TBL] [Abstract][Full Text] [Related]
20. Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China.
Liu T; Wu J; Na P; Wu X; Yuan Y; Wang C; Ma X; Qi L; Chen X; Rao W; Duan Z; Fang X; Xie L; Li H
BMC Geriatr; 2024 Jun; 24(1):487. PubMed ID: 38831261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
